← ANALYST RATINGS · TIPRANKS
Quanterix (QTRX): analyst forecast and price target
Analyst consensus
Hold0 Buy2 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $3.25, the highest $3.50, the lowest $3.00. The average is +13.2% from the last price of $2.87.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $3.00 → $3.50+16.7% | Hold | +22.0% | Reiterated | 13.10.26on TipRanks 08:41 | −0.3%next day −1.8% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +4.5% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +4.5% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $3.00 | Hold | +4.5% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Sell | +4.5% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $3.00 | Hold | +4.5% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +22.0% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $4.00 → $3.00−25.0% | Hold | +4.5% | Reiterated | 17.08.26on TipRanks 07:21 | +13.2%next day −7.5% · 5 days −2.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Quanterix
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.00 at a price of $3.71 (−19.1%); now: $3.25 at $2.87 (+13.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 4 | 3 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.42 (from $-0.48 to $-0.39). Last quarter: $-1.04.
Sales
Next quarter’s sales estimate — $34M (from $33M to $34M). Last quarter: $33M.
Best top-analyst consensus in the sector · Healthcare
About Quanterix
- CEO: Everett V. Cunningham
- Employees: 450
- Building 1, Billerica, MA, 01821, US
- www.quanterix.com
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Data from the stock’s TipRanks forecast page, read 102 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗